Search results for "rituximab."

showing 2 items of 152 documents

THU0045 IL-25/IL-17RB AXIS IS ACTIVATED AND ASSOCIATED WITH ILC2 EXPANSION IN GRANULOMATOSIS WITH POLYANGIITIS (GPA)

2019

Background: Pathogenesis of Granulomatosis with polyangiitis (GPA) is still unknown. However, it has been observed a skewing of circulating CD4+ T cells toward the Th17 and Th2 phenotype. The pro-inflammatory cytokine interleukin 25 (IL-25) is a member of IL-17 cytokine family associated to the Th2 immune phenotype. Through the receptor IL17RB, IL-25 further sustains the Th2-type immune response and elicits the expansion of the type 2 innate lymphoid cells (ILC2) and M2 macrophages. A pathogenic role of the innate lymphoid cells in GPA has been recently demonstrated; however, the relevance of IL-25 in this condition remains unexplored. Objectives: Aim of the study was to evaluate the expres…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentInnate lymphoid cellConsensus conferenceGATA3medicine.diseaseGastroenterologyPathogenesisImmune systemCytokineInternal medicineMedicineRituximabbusinessGranulomatosis with polyangiitismedicine.drugPoster Presentations
researchProduct

Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?

2020

Summary The current SARS‐CoV‐2 pandemic particularly endangers older people with pre‐existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID‐19 disease. In principle though, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases because of the SARS‐CoV‐2 pandemic. However, since there is currently neither an effective therapy nor corresponding vaccination protection, the indication for a prolonged immunosuppressive therapy should be made with special care. In parti…

medicine.medical_specialtymedicine.medical_treatment610 MedizinDiseaseReviewDermatologyAntiviral Agents030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChloroquine610 Medical sciencesPandemicMedicineHumansIntensive care medicineImmunosuppression Therapybusiness.industryCOVID-19HydroxychloroquineImmunosuppressionChloroquineCOVID-19 Drug TreatmentCalcineurinVaccinationDoxycyclineRituximabbusinessmedicine.drugHydroxychloroquineJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct